Key Market Indicator:
F&G: 40
25.233,35 NASDAQ · 48.573,00 DOW · 6.841,40 S&P · 4.299,43 Gold · 61,01 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© BusinessWire
08.12.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the prese...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
News Preview
AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genom...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Reports Q3 2025 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substant...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
07.10.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6, 2025 Stifel Healthcare Conference, November 11-13, 2025 Jefferies Global Healthcare Conference, November 18-20, 2025 Piper Sandler 37th Annual Healthcare Conference, Decemb...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
29.09.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations w...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
News Preview
AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of ind...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
News Preview
AbCellera (Nasdaq: ABCL) today announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 targets OX40...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations we...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
News Preview
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential application...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
News Preview
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), co...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
News Preview
AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 (“the ‘408 Patent”). AbCellera’s ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Pre...
Themefolio
Profiler
Peergroup
© BusinessWire
10.05.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
News Preview
AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California. AbCellera’s presentation, which is available for viewing here, describes key properties of ABCL575, including: Potent functio...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.05.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Reports Q1 2025 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30, 2025. Targeting prostate-specific membrane antigen (PSMA) with a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in May and June
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Bloom Burton & Co. Healthcare Investor Conference, May 5-6 Goldman Sachs 46th Annual Global Healthcare conference, June 9-11 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois. Details on AbCellera’s poster prese...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Reports Full Year 2024 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and compl...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in March
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health Care Conference, March 3-5 KeyBanc Capital Markets Healthcare Forum, March 18-19 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics Inc. AbCellera...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations webs...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
News Preview
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Present at Upcoming Investor Conferences in December and January
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on W...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera’s presentation, which is available for viewing here, describes: Strategies to address key c...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Reports Q3 2024 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Present at Upcoming Investor Conferences in November 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas. Details on AbCellera’s poster presentation at SITC are as follows: Title: Profiling bispecific T-cell engagers: Strategies...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
News Preview
AbCellera (Nasdaq: ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations webs...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
ISIN: CA00288U1066

Abcellera Biologics Inc
ABCL

LISTED

NASDAQ
AbCellera to Present at Upcoming Investor Conferences in September
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:30 a.m. Pacific Time...
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 14.12.2025, Calendar Week 50, 348th day of the year, 17 days remaining until EoY.